Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment
Sign Up to like & getrecommendations! Published in 2021 at "Obesity Medicine"
DOI: 10.1016/j.obmed.2020.100312
Abstract: COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those… read more here.
Keywords: treatment; glp agonists; friend foe; foe ace2 ... See more keywords
Asthma Exacerbations in Type 2 Diabetics with Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Sign Up to like & getrecommendations! Published in 2020 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.202004-0993oc
Abstract: RATIONALE Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and hyperresponsiveness in preclinical models. OBJECTIVES To compare rates of asthma exacerbations and symptoms… read more here.
Keywords: glp agonists; like peptide; peptide receptor; glucagon like ... See more keywords
A Review of the Renoprotective Effects of Novel Antidiabetic Agents
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190020902344
Abstract: The objective of this review article was to identify and examine current evidence surrounding the potential renoprotective effects of newer antidiabetic agents such as sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucose-like peptide 1 (GLP-1) agonists, and… read more here.
Keywords: review renoprotective; sglt inhibitors; renoprotective effects; inhibitors glp ... See more keywords
PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvac150.782
Abstract: Abstract Introduction Glucagon-like Peptide 1 (GLP-1) agonists are efficacious glycemic control and weight loss agents for obese patients with or without type 2 diabetes mellitus. Use of GLP-1 agonists for patients with type 1 diabetes… read more here.
Keywords: meta analysis; glp agonists; analysis; type diabetes ... See more keywords
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0217701
Abstract: Background The last international consensus on the management of type 2 diabetes (T2D) recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV) disease; metformin remains the first-line glucose lowering medication. Last studies… read more here.
Keywords: risk; analysis; sglt inhibitors; mortality ... See more keywords
The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Endocrinology and Metabolism"
DOI: 10.1515/jpem-2021-0533
Abstract: Abstract Background The incidence of type 2 diabetes mellitus (T2DM) in the pediatric population is increasing. There is a great need to develop more drugs for pediatric T2DM. Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl dipeptidase-4… read more here.
Keywords: glp agonists; dpp inhibitors; glucagon like; type diabetes ... See more keywords
1031-P: Impact of the Cardioprotective Effects of GLP-1 Agonists in the Management of Diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1031-p
Abstract: Introduction: Cardiovascular disease is the principal cause of mortality in the diabetic population. Diabetic-cardiomyopathy increases the risk of heart failure in diabetics independently of coronary artery disease. It is characterized by ventricular dilation, myocardial fibrosis… read more here.
Keywords: impact cardioprotective; none; glp agonists; cardioprotective effects ... See more keywords
812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-812-p
Abstract: GLP-1 agonists and SGLT2 inhibitors are increasingly prescribed as second line agents for type 2 diabetes. However, costs for these drugs are high. Pharmaceutical manufacturers often cite high development costs as a justification for high… read more here.
Keywords: industry; nih academia; agonists sglt2; glp agonists ... See more keywords
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1033479
Abstract: Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the… read more here.
Keywords: mechanism efficacy; disease; alzheimer disease; glp agonists ... See more keywords
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2023.1085799
Abstract: Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to… read more here.
Keywords: receptor agonists; glp agonists; glp receptor; obesity ... See more keywords